STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Abstract Background The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in both tumorigenesis and activation of immune responses. In diffuse large B-cell l...

詳細記述

保存先:
書誌詳細
主要な著者: Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina Piha-Paul, Murali V. P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2018-11-01
シリーズ:Journal for ImmunoTherapy of Cancer
主題:
STAT3
Anti-sense oligonucleotide
Diffuse large B-cell lymphoma
DLBCL
Clinical trial
Immunotherapy
オンライン･アクセス:http://link.springer.com/article/10.1186/s40425-018-0436-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料